Clinical Trials in Pittsburgh

Showing 2441-2460 of 18,076 trials

Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

NCT05444465

The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique 'Completion and Repair' for surgically treating partial-thickness rotator cuff tears.

Rotator Cuff Injuries

Smith & Nephew, Inc.234 participantsStarted Aug 2022

Rome, Georgia, United States • Rockford, Illinois, United States • Baltimore, Maryland, United States +17 more locations

RECRUITINGPhase 2< 1 mile

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Oligometastatic Prostate CarcinomaProstate AdenocarcinomaProstate Ductal Adenocarcinoma+2 more

NRG Oncology194 participantsStarted Apr 2022

Phoenix, Arizona, United States • Berkeley, California, United States • Beverly Hills, California, United States +236 more locations

Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Find Trials by Condition in Pittsburgh

Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Phase III Trial of Sirolimus in IBM

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

Prostate Active Surveillance Study

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma